Currency In USD
| Previous Close | 2.6 |
| Open | 2.55 |
| Day High | 2.55 |
| Day Low | 1.84 |
| 52-Week High | 1,491.84 |
| 52-Week Low | 1.84 |
| Volume | 12.62M |
| Average Volume | 42,102 |
| Market Cap | 1.7M |
| PE | -0.06 |
| EPS | -37.97 |
| Moving Average 50 Days | 4.05 |
| Moving Average 200 Days | 35.54 |
| Change | -0.5 |
NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
GlobeNewswire Inc.
Mar 10, 2026 11:30 AM GMT
NEWPORT BEACH, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly o
NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
GlobeNewswire Inc.
Feb 19, 2026 12:30 PM GMT
NEWPORT BEACH, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences, Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the filing of ten (10) new U.S. patent applicat
NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health
GlobeNewswire Inc.
Feb 11, 2026 12:30 PM GMT
NEWPORT BEACH, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced that it has executed a de